The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis

Summary

The contribution of the factor Va C1 domain (fVa-C1) to assembly of the prothrombinase complex has not been previously investigated. The homologous fVa-C2 domain contains a binding site for phosphatidylserine (PS) that includes the indole moieties of Trp²⁰⁶³/Trp²⁰⁶⁴ at the apex of spike-1. In order to investigate the structure and function of fVa-C1 a molecular model was constructed based on the structure of fVa-C2. The aromatic and hydrophobic side chains of Tyr¹⁹⁵⁶/Leu¹⁹⁵⁷ in fVaC1 are located at the predicted apex of spike-3. Exposed charged and hydrophobic residues in fVa-C1 were changed to alanine in clusters of 1-3 mutations per construct. The resultant 20 mutants were expressed in COS cells and screened for binding to immobilized PS and prothrombinase activity on phospholipid vesicles containing either 25% or 5% PS. Two mutants, (Y1956,L1957)A, and (R2023,R2027)A showed both decreased binding to immobilized PS and a selective decrease in prothrombinase activity on membranes containing 5% PS. The interaction of purified (Y1956,L1957)A with phospholipid vesicles was studied using fluorescence resonance energy transfer and prothrombinase assays. The affinity of (Y1956,L1957)A binding to 25% PS membranes was reduced 12-fold compared to rHFVa. Prothrombin activation in the presence of (Y1956,L1957)A was markedly impaired on phospholipid vesicles containing 10% or less PS. We conclude that solvent exposed hydrophobic and aromatic amino acids in both fVa-C1 and fVa-C2 contribute to the interaction of factor V with PS membranes.

Keywords

Factor VIII - factor V - phospholipids / procoagulant - site-directed mutagenesis

^* Both authors contributed equally to this work.

• References

• 1 Kane WH, Factor V. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. New York, NY: Lippincott; 2000
• 2 Mann KG, Kalafatis M, Factor V. a combination of Dr. Jekyll and Mr. Hyde. Blood 2003; 101 (01) 20-30.
• 3 Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988; 263: 3823-34.
• 4 Kane WH, Davie EW. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc Natl Acad Sci U S A 1986; 83: 6800-4.
• 5 Jenny RJ, Pittman DD, Toole JJ. et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A 1987; 84: 4846-50.
• 6 Kane WH, Ichinose A, Hagen FS. et al. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 1987; 26: 6508-14.
• 7 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-55.
• 8 Tracy PB, Mann KG. Prothrombinase complex assembly on the platelet surface is mediated through the 74,000-dalton component of factor Va. Proc Natl Acad Sci U S A 1983; 80: 2380-4.
• 9 Saenko EL, Scandella D, Yakhyaev AV. et al. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem 1998; 273 (43) 27918-26.
• 10 Ortel TL, Devore-Carter D, Quinn-Allen MA. et al. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem 1992; 267: 4189-98.
• 11 Ortel TL, Quinn-Allen MA, Charles LA. et al. Characterization of an acquired inhibitor to coagulation Factor V. Antibody binding to the second C-type domain of Factor V inhibits the binding of Factor V to phosphatidylserine and neutralizes procoagulant activity. J Clin Invest 1992; 90: 2340-7.
• 12 Ortel TL, Quinn-Allen MA, Keller FG. et al. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. J Biol Chem 1994; 269: 15898-905.
• 13 Kim SW, Quinn-Allen MA, Camp T. et al. Identification of functionally important amino acid residues within the C2 domain of human factor V using alanine scanning mutagenesis. Biochemistry 2000; 39: 1951-8.
• 14 Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-84.
• 15 Foster PA, Fulcher CA, Houghten RA. et al. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75: 1999-2004.
• 16 Macedo-Ribeiro S, Bode W, Huber R. et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402 6760 434-9.
• 17 Pratt KP, Shen BW, Takeshima K. et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402 6760 439-42.
• 18 Nicolaes GA, Villoutreix BO, Dahlback B. Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex. Blood Coagul Fibrinolysis 2000; 11 (01) 89-100.
• 19 Gilbert GE, Kaufman RJ, Arena AA. et al. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factorbinding motifs. J Biol Chem 2002; 277 (08) 6374-81.
• 20 Srivastava A, Quinn-Allen MA, Kim SW. et al. Soluble phosphatidylserine binds to a single identified site in the C2 domain of human factor Va. Biochemistry 2001; 40 (28) 8246-55.
• 21 Turk D. Weiterentwicklung eines Programms für Molekülgraphik und Elecktronendichte-Manipulation und seine Anwendung auf verschiedene Protein-Strukturaufklärungen. München: Technische Universität. 1992
• 22 Nicholls A, Sharp KA, Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 1991; 11 (04) 281-296.
• 23 Kane WH, Devore-Carter D, Ortel TL. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. Biochemistry 1990; 29: 6762-8.
• 24 Kim SW, Ortel TL, Quinn-Allen MA. et al. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry 1999; 38 (35) 11448-54.
• 25 Krishnaswamy S, Mann KG. The binding of factor Va to phospholipid vesicles. J Biol Chem 1988; 263: 5714-23.
• 26 Gomori GA. A modification of the colorimetric phosphorus determination for use with the photoelectric colorimeter. J Lab Clin Med 1942; 27: 955-60.
• 27 Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J Biol Chem 1990; 265: 815-22.
• 28 Ito N, Phillips SE, Yadav KD. et al. Crystal structure of a free radical enzyme, galactose oxidase. J Mol Biol 1994; 238: 794-814.
• 29 Guinto ER, Esmon CT, Mann KG. et al. The complete cDNA sequence of bovine coagulation factor V. J Biol Chem 1992; 267: 2971-8.
• 30 Grimm DR, Colter MB, Braunschweig M. et al. Porcine factor V: cDNA cloning, gene mapping, three-dimensional protein modeling of membrane binding sites and comparative anatomy of domains. Cell Mol Life Sci 2001; 58 (01) 148-59.
• 31 Yang TL, Cui J, Rehumtulla A. et al. The structure and function of murine factor V and its inactivation by protein C. Blood 1998; 91: 4593-9.
• 32 Cunningham BC, Wells JA. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 1989; 244: 1081-5.
• 33 Pellequer JL, Gale AJ, Griffin JH. et al. Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. Blood Cells Mol Dis 1998; 24: 448-61.
• 34 Fuentes-Prior P, Fujikawa K, Pratt KP. New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr Protein Pept Sci 2002; 03 (03) 313-39.
• 35 Stahelin RV, Cho W. Differential roles of ionic, aliphatic, and aromatic residues in membrane-protein interactions: a surface plasmon resonance study on phospholipases A2. Biochemistry 2001; 40 (15) 4672-8.
• 36 Yamazaki T, Nicolaes GA, Sorensen KW. et al. Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype. Blood 2002; 100 (07) 2515-21.
• 37 Izumi T, Kim SW, Greist A. et al. Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding. Thromb Haemost 2001; 85 (06) 1048-54.
• 38 Kojima Y, Heeb MJ, Gale AJ. et al. Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va. J Biol Chem 1998; 273: 14900-5.
• 39 Kalafatis M, Beck DO. Identification of a binding site for blood coagulation factor Xa on the heavy chain of factor Va. Amino acid residues 323-331 of factor V represent an interactive site for activated factor X. Biochemistry 2002; 41 (42) 12715-28.
• 40 Steen M, Villoutreix BO, Norstrom EA. et al. Defining the factor Xa-binding site on factor Va by site-directed glycosylation. J Biol Chem 2002; 277 (51) 50022-9.
• 41 Kalafatis M, Xue J, Lawler CM, Mann KG. Contribution of the heavy and light chains of factor Va to the interaction with factor Xa. Biochemistry 1994; 33: 6538-45.
• 42 Zhai X, Srivastava A, Drummond DC. et al. Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va. Biochemistry 2002; 41 (17) 5675-84.
• 43 Majumder R, Weinreb G, Zhai X. et al. Soluble phosphatidylserine triggers assembly in solution of a prothrombin-activating complex in the absence of a membrane surface. J Biol Chem 2002; 277 (33) 29765-73.
• 44 Stoylova SS, Lenting PJ, Kemball-Cook G. et al. Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers. J Biol Chem 1999; 274 (51) 36573-8.
• 45 Stoylova S, Mann KG, Brisson A. Structure of membrane-bound human factor Va. FEBS Lett 1994; 351: 330-4.